Phase I Clinical Trials CROs in Canada
8 published
8 published CROs match Phase I Clinical Trials in Canada.
Locations in this set include Canada, United States, United Kingdom, Australia, France, and Germany.
Capabilities that show up most often in this set: Small Molecule, Biologics (Other), Gene Therapy, Biologics (Monoclonal Antibodies), and Cell Therapy.
Matching companies
AltasciencesMid-size early phase CRO/CDMO in Canada and the U.S. offering preclinical safety testing, clinical pharmacology (Phase I–II), bioanalysis, research services, and manufacturing with integrated capabilities.
BioPharma Services Inc.Full-service Phase 1 CRO specializing in early-stage clinical trials, bioequivalence/bioavailability studies, and human abuse potential assessments with state-of-the-art facilities in Toronto and in-house bioanalytical labs.
CelerionGlobal CRO specializing in early-phase clinical research and bioanalytical sciences with 650+ beds across 30 countries and 50+ years of experience.- JSS Medical ResearchFull-service CRO with over 30 years of experience offering clinical trials, biostatistics, medical writing, and health economics services across all phases of development.
Pharma Medica Research Inc.Canadian CRO running early-phase clinical trials from a 24-bed Phase I unit, with in-house bioanalysis under a 21 CFR Part 11-compliant laboratory data management system. Its scientific affairs team supports protocol design, biostatistics, and submission-ready reports.
Premier ResearchPremier Research is a global full-service CRO delivering clinical research and development solutions across the complete drug development lifecycle. The organization provides comprehensive capabilities spanning study design, study startup, medical affairs, biostatistics and data management, central monitoring, clinical monitoring and site management, project and risk management, safety and pharmacovigilance, quality and compliance, and medical writing.
Syneos HealthGlobal CRO with 26,000+ employees offering integrated clinical development, regulatory affairs, and commercialization services. Helped develop or commercialize 96% of FDA-approved oncology drugs and 93% of EMA-authorized oncology products in the last five years.
TFS HealthScienceGlobal mid-size CRO specializing in dermatology, internal medicine, neuroscience, oncology, and ophthalmology with Phase I-IV clinical development, real-world evidence studies, and flexible resourcing solutions across 600+ experts in Europe, North America, and Australia.
Markdown mirror: /services/phase-1-clinical-trials/canada.md